Contineum Therapeutics Future Growth
Future criteria checks 0/6
Contineum Therapeutics's revenue is forecast to decline at 76.1% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 27.6% |
Revenue growth rate | -76.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 May 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | N/A | -68 | -71 | 1 |
12/31/2025 | 15 | N/A | -42 | -29 | 2 |
12/31/2024 | N/A | N/A | -37 | -37 | 2 |
3/31/2024 | 50 | 0 | 16 | 17 | N/A |
12/31/2023 | 50 | 3 | 19 | 19 | N/A |
9/30/2023 | 50 | -3 | 26 | 26 | N/A |
12/31/2022 | N/A | -24 | -20 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CTNM's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if CTNM's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CTNM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CTNM's revenue is expected to decline over the next 3 years (-76.1% per year).
High Growth Revenue: CTNM's revenue is forecast to decline over the next 3 years (-76.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTNM's Return on Equity is forecast to be high in 3 years time